File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: WATCHMAN device-related thrombus successfully treated with apixaban: A case report

TitleWATCHMAN device-related thrombus successfully treated with apixaban: A case report
Authors
Keywordsapixaban
atrial fibrillation
device related thrombus
left atrial appendage occlusion
stroke
Issue Date2017
PublisherLippincott, Williams & Wilkins: Various Creative Commons. The Journal's web site is located at http://journals.lww.com/md-journal/pages/default.aspx
Citation
Medicine, 2017, v. 96 n. 47, article no. e8693 How to Cite?
AbstractRationale: Among atrial fibrillation patients with high risk of bleeding, left atrial appendage occlusion has emerged as an alternative to long-term oral anticoagulation therapy for stroke prevention. Device-related thrombus remains a major concern because it may result in recurrent embolic events. To date, there is no consensus on the optimal method of treating device-related-thrombus. Patient concerns: A 78-year-old man with atrial fibrillation had an episode of intracranial hemorrhage while taking warfarin. He subsequently underwent percutaneous placement of a 30-mm Watchman device to the left atrial appendage. He was prescribed dual anti-platelet therapy with aspirin and clopidogrel. Diagnosis: Reassessment echocardiography 3 months later found device-related thrombus. Interventions: The antithrombotic regimen was switched from dual antiplatelet therapy to apixaban. Outcomes: Reassessment echocardiography 3 months later revealed complete resolution of the device-related thrombus. Apixaban was stopped. He had dual antiplatelet therapy for 6 more months followed by life-long aspirin. There was no bleeding complication since implantation of Watchman device. Lessons: We demonstrated successful treatment of device-related thrombus with a short course of apixaban with complete resolution of thrombus. Further randomized controlled trials are required to determine the choice and duration of drug therapy for device-related thrombus.
Persistent Identifierhttp://hdl.handle.net/10722/261820
ISSN
2023 Impact Factor: 1.3
2023 SCImago Journal Rankings: 0.441
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, CK-
dc.contributor.authorChan, PHM-
dc.contributor.authorLam, CCS-
dc.contributor.authorKwok, OH-
dc.contributor.authorLam, YY-
dc.contributor.authorSiu, DCW-
dc.date.accessioned2018-09-28T04:48:40Z-
dc.date.available2018-09-28T04:48:40Z-
dc.date.issued2017-
dc.identifier.citationMedicine, 2017, v. 96 n. 47, article no. e8693-
dc.identifier.issn0025-7974-
dc.identifier.urihttp://hdl.handle.net/10722/261820-
dc.description.abstractRationale: Among atrial fibrillation patients with high risk of bleeding, left atrial appendage occlusion has emerged as an alternative to long-term oral anticoagulation therapy for stroke prevention. Device-related thrombus remains a major concern because it may result in recurrent embolic events. To date, there is no consensus on the optimal method of treating device-related-thrombus. Patient concerns: A 78-year-old man with atrial fibrillation had an episode of intracranial hemorrhage while taking warfarin. He subsequently underwent percutaneous placement of a 30-mm Watchman device to the left atrial appendage. He was prescribed dual anti-platelet therapy with aspirin and clopidogrel. Diagnosis: Reassessment echocardiography 3 months later found device-related thrombus. Interventions: The antithrombotic regimen was switched from dual antiplatelet therapy to apixaban. Outcomes: Reassessment echocardiography 3 months later revealed complete resolution of the device-related thrombus. Apixaban was stopped. He had dual antiplatelet therapy for 6 more months followed by life-long aspirin. There was no bleeding complication since implantation of Watchman device. Lessons: We demonstrated successful treatment of device-related thrombus with a short course of apixaban with complete resolution of thrombus. Further randomized controlled trials are required to determine the choice and duration of drug therapy for device-related thrombus.-
dc.languageeng-
dc.publisherLippincott, Williams & Wilkins: Various Creative Commons. The Journal's web site is located at http://journals.lww.com/md-journal/pages/default.aspx-
dc.relation.ispartofMedicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectapixaban-
dc.subjectatrial fibrillation-
dc.subjectdevice related thrombus-
dc.subjectleft atrial appendage occlusion-
dc.subjectstroke-
dc.titleWATCHMAN device-related thrombus successfully treated with apixaban: A case report-
dc.typeArticle-
dc.identifier.emailChan, PHM: phmchan@hku.hk-
dc.identifier.emailLam, CCS: scclam@hku.hk-
dc.identifier.emailSiu, DCW: cwdsiu@hkucc.hku.hk-
dc.identifier.authorityChan, PHM=rp01864-
dc.identifier.authoritySiu, DCW=rp00534-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1097/MD.0000000000008693-
dc.identifier.pmid29381951-
dc.identifier.pmcidPMC5708950-
dc.identifier.scopuseid_2-s2.0-85036561830-
dc.identifier.hkuros293236-
dc.identifier.volume96-
dc.identifier.issue47-
dc.identifier.spagearticle no. e8693-
dc.identifier.epagearticle no. e8693-
dc.identifier.isiWOS:000417645700042-
dc.publisher.placeUnited States-
dc.identifier.issnl0025-7974-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats